ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0890

Long Term Efficacy of a 2-year MRI Treat-to-target Treatment Strategy on Disease Activity, MRI Inflammation and Physical Function in Rheumatoid Arthritis Patients in Clinical Remission: Five Year Follow-up of the IMAGINE-RA Cohort

Signe Møller-Bisgaard1, Kim Hørslev-Petersen2, Daniel Glinatsi3, Bo Ejbjerg4, Merete Lund Hetland5, Jakob Møllenbach Møller6, Robin Christensen7, Sabrina Mai Nielsen8, Mikael Boesen9, Kristian Stengaard-Pedersen10, Ole Rintek Madsen11, Bente Jensen12, Jan Alexander Villadsen13, Ellen Margrethe Hauge10, Oliver Hendricks2, Hanne Merete Lindegaard14, Niels Steen Krogh15, Anne Grethe Jurik16, Henrik Thomsen17 and Mikkel Østergaard18, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 2Department of Rheumatology, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, 3Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, 4Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, 5Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, 6Department of Radiology, Herlev-Gentofte Hospital, Copenhagen, Denmark, 7Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, 8The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, 9Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark, 10Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 11Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Herlev-Gentofte, Copenhagen, Denmark, 12Center for Rheumatology and Spine Diseases, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark, 13Department of Rheumatology, Silkeborg Hospital, Silkeborg, Denmark, 14Department of Rheumatology, Odense University Hospital, Odense, Denmark, 15ZiteLab ApS, Frederiksberg, Denmark, 16Department of Radiology, Aarhus University Hospital, Aarhus, Denmark, 17Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark, 18Rigshospitalet, University of Copenhagen, Glostrup, Denmark

Meeting: ACR Convergence 2022

Keywords: clinical trial, Disease Activity, Magnetic resonance imaging (MRI), Outcome measures, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Targeting MRI remission in rheumatoid arthritis (RA) patients in clinical remission may improve long term clinical, functional and MRI outcomes. The purpose of the IMAGINE-MORE study was to investigate whether a 2-year MRI treat-to-target (T2T) strategy, based on structured MRI assessments targeting absence of osteitis combined with clinical remission, compared with a conventional clinical T2T strategy targeting clinical remission only, improves disease activity, physical function and suppresses MRI-inflammation over 5 years in RA patients.

Methods: The IMAGINE-MORE trial was designed as an extension protocol to the 2-year, IMAGINE-RA randomized trial. IMAGINE-RA included 200 RA patients in clinical remission (DAS28-CRP< 3.2 AND no swollen joints) who received conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and investigated whether an MRI T2T strategy targeting absence of osteitis in combination with clinical remission (DAS28-CRP≤3.2 and no swollen joints) could increase remission rates and prevent erosive progression compared with a conventional T2T strategy targeting clinical remission only. If treatment target was not met, treatment was escalated according to a predefined treatment algorithm starting with increment in csDMARDs and then adding biologics. At the end of the study, participants were invited to participate in the IMAGINE-MORE follow-up study and informed consent was obtained. Patients were managed in routine outpatient clinic applying a conventional treatment strategy targeting clinical remission. Protocolized clinical visits (year 3, 4 and 5) and contrast-enhanced MRI of the dominant hand 2nd-5th metacarpophalangeal joints (year 3 and 5) were carried out. The primary clinical endpoint was the proportion of patients achieving DAS28-CRP remission (DAS28-CRP< 2.6) at year 5. Predefined key secondary outcomes were disease activity (DAS28-CRP), and changes in MRI osteitis (OMERACT RA MRI scoring system (RAMRIS)) and functional level (HAQ) from baseline to 5 years follow up. Endpoints were analysed by logistic regression models (dichotomous endpoints) and repeated measures mixed effects models (continuous outcomes) adjusted for propensity scores corresponding to (remaining in) group allocation.

Results: Fifty-nine patients in the MRI T2T arm and 72 patients in conventional T2T arm consented to participate. Of these, 47 patients (80%) in the MRI T2T group and 54 patients (75%) in the conventional T2T group reached the primary clinical endpoint (OR= 2.00 [95%CI: 0.76 to 5.28]) (Table and Figure). No statistically significant differences between treatment strategies in the primary and key secondary outcomes were seen.

Conclusion: A two-year MRI T2T strategy targeting absence of MRI osteitis combined with clinical remission as compared to a conventional clinical T2T strategy in RA patients in clinical remission had no effect on the long-term probability of achieving DAS28-CRP remission. In accordance with the primary results from IMAGINE-RA trial, these long-term data do not support the use of an MRI-guided strategy for treating patients with RA in clinical remission.

Ref: Møller-Bisgaard S et al: JAMA 2019, 321(5):461-472.

Supporting image 1

Table: Group estimates are presented as no. (%) for dichotomous data and least squares means (SE) for continuous data. For the primary endpoint, adjusted odds ratio and 95%CI between groups were calculated from a logistic regression model including a fixed factor for treatment arm, and an adjustment for propensity score as a covariate. For endpoints with continuous data, least squares mean differences between groups were calculated based on repeated-measures mixed linear models adjusted for baseline values and propensity scores. 1Missing data for one patient in the conventional T2T group.

Supporting image 2

Figure: Absolute scores from baseline to 5 years in DAS28-CRP and proportions in remission Illustrating the trajectory of absolute scores from baseline to month 60 (i.e. 5 years) in DAS28-CRP based on a mixed model with an adjustment for baseline and propensity scores, as well as proportions in DAS28 remission over time for each group, with non-responder imputation.


Disclosures: S. Møller-Bisgaard, AbbVie; K. Hørslev-Petersen, None; D. Glinatsi, Eli Lilly, AbbVie/Abbott; B. Ejbjerg, None; M. Hetland, Sandoz, Novartis, Eli Lilly, Medac, Pfizer; J. Møllenbach Møller, None; R. Christensen, None; S. Nielsen, None; M. Boesen, None; K. Stengaard-Pedersen, None; O. Rintek Madsen, None; B. Jensen, None; J. Alexander Villadsen, None; E. Hauge, None; O. Hendricks, None; H. Lindegaard, None; N. Krogh, None; A. Jurik, None; H. Thomsen, None; M. Østergaard, AbbVie/Abbott, Amgen, Bristol-Myers Squibb(BMS), Celgene, Eli Lilly, Janssen, Gilead, Novartis, Pfizer, UCB.

To cite this abstract in AMA style:

Møller-Bisgaard S, Hørslev-Petersen K, Glinatsi D, Ejbjerg B, Hetland M, Møllenbach Møller J, Christensen R, Nielsen S, Boesen M, Stengaard-Pedersen K, Rintek Madsen O, Jensen B, Alexander Villadsen J, Hauge E, Hendricks O, Lindegaard H, Krogh N, Jurik A, Thomsen H, Østergaard M. Long Term Efficacy of a 2-year MRI Treat-to-target Treatment Strategy on Disease Activity, MRI Inflammation and Physical Function in Rheumatoid Arthritis Patients in Clinical Remission: Five Year Follow-up of the IMAGINE-RA Cohort [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/long-term-efficacy-of-a-2-year-mri-treat-to-target-treatment-strategy-on-disease-activity-mri-inflammation-and-physical-function-in-rheumatoid-arthritis-patients-in-clinical-remission-five-year-foll/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-efficacy-of-a-2-year-mri-treat-to-target-treatment-strategy-on-disease-activity-mri-inflammation-and-physical-function-in-rheumatoid-arthritis-patients-in-clinical-remission-five-year-foll/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology